Halozyme Therapeutics, Inc. $HALO Shares Sold by New York State Teachers Retirement System

New York State Teachers Retirement System cut its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 0.2% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 126,980 shares of the biopharmaceutical company’s stock after selling 234 shares during the period. New York State Teachers Retirement System owned approximately 0.10% of Halozyme Therapeutics worth $6,605,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in HALO. Wealth Preservation Advisors LLC acquired a new position in shares of Halozyme Therapeutics during the first quarter worth approximately $32,000. SVB Wealth LLC acquired a new position in shares of Halozyme Therapeutics during the first quarter worth approximately $33,000. Bessemer Group Inc. lifted its position in Halozyme Therapeutics by 62.9% in the first quarter. Bessemer Group Inc. now owns 536 shares of the biopharmaceutical company’s stock worth $34,000 after purchasing an additional 207 shares during the period. Brooklyn Investment Group lifted its position in Halozyme Therapeutics by 1,558.1% in the first quarter. Brooklyn Investment Group now owns 713 shares of the biopharmaceutical company’s stock worth $45,000 after purchasing an additional 670 shares during the period. Finally, Park Place Capital Corp lifted its position in Halozyme Therapeutics by 20.1% in the first quarter. Park Place Capital Corp now owns 1,086 shares of the biopharmaceutical company’s stock worth $69,000 after purchasing an additional 182 shares during the period. 97.79% of the stock is currently owned by institutional investors and hedge funds.

Halozyme Therapeutics Price Performance

NASDAQ HALO opened at $67.03 on Monday. The stock has a market capitalization of $7.84 billion, a P/E ratio of 15.34, a P/E/G ratio of 0.36 and a beta of 1.16. Halozyme Therapeutics, Inc. has a 1 year low of $42.01 and a 1 year high of $79.50. The business’s fifty day moving average is $71.56 and its two-hundred day moving average is $62.09. The company has a debt-to-equity ratio of 4.54, a quick ratio of 7.01 and a current ratio of 8.36.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $1.54 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.23 by $0.31. The company had revenue of $325.72 million for the quarter, compared to analysts’ expectations of $282.66 million. Halozyme Therapeutics had a return on equity of 150.85% and a net margin of 47.28%.The firm’s revenue was up 40.8% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.91 earnings per share. Halozyme Therapeutics has set its FY 2025 guidance at 6.000-6.400 EPS. On average, research analysts forecast that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

Insider Buying and Selling at Halozyme Therapeutics

In other Halozyme Therapeutics news, CEO Helen Torley sold 20,000 shares of the company’s stock in a transaction on Wednesday, October 1st. The stock was sold at an average price of $75.35, for a total value of $1,507,000.00. Following the transaction, the chief executive officer owned 733,719 shares of the company’s stock, valued at approximately $55,285,726.65. This represents a 2.65% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Bernadette Connaughton sold 4,000 shares of the business’s stock in a transaction on Tuesday, September 2nd. The shares were sold at an average price of $73.68, for a total transaction of $294,720.00. Following the sale, the director directly owned 46,952 shares in the company, valued at approximately $3,459,423.36. This trade represents a 7.85% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 108,227 shares of company stock valued at $7,779,595. Corporate insiders own 2.90% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on the company. JPMorgan Chase & Co. upped their target price on Halozyme Therapeutics from $60.00 to $63.00 and gave the stock a “neutral” rating in a research report on Thursday, August 7th. Benchmark upped their target price on Halozyme Therapeutics from $75.00 to $90.00 and gave the stock a “buy” rating in a research report on Wednesday, September 24th. Leerink Partners upgraded Halozyme Therapeutics from an “underperform” rating to a “market perform” rating and set a $70.00 target price for the company in a research report on Tuesday, October 14th. Zacks Research downgraded Halozyme Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Monday, October 6th. Finally, Leerink Partnrs upgraded Halozyme Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Tuesday, October 14th. Five research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $73.00.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.